The strategy is focused on creating and building life science companies addressing commercially attractive markets in diseases of high unmet medical needs.
The team has an average experience of 27 years in the sector, with extensive investment track records alongside deep operational experience in drug discovery and development.
- Western Europe
- United States
The Life Sciences strategy aims to build a portfolio of c.15 to 20 preclinical and clinical stage growth opportunities with equity investments of $20-100m per company.
Life Sciences events calendar
Meet the Life Sciences team
Explore our portfolio companies
Amolyt Pharma is a clinical stage biotechnology company working to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
CuraSen Therapeutics is a clinical-stage company developing small molecule therapies to treat neurodegenerative disease.
Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.